These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21219436)

  • 1. Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart.
    Ihlo CA; Lauritzen T; Sturis J; Skyggebjerg O; Christiansen JS; Laursen T
    Diabet Med; 2011 Feb; 28(2):230-6. PubMed ID: 21219436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
    Heise T; Zijlstra E; Nosek L; Rikte T; Haahr H
    Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
    Heise T; Meiffren G; Alluis B; Seroussi C; Ranson A; Arrubla J; Correia J; Gaudier M; Soula O; Soula R; DeVries JH; Klein O; Bode B
    Diabetes Obes Metab; 2019 Apr; 21(4):1066-1070. PubMed ID: 30565407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
    Hirsch IB; Bode BW; Garg S; Lane WS; Sussman A; Hu P; Santiago OM; Kolaczynski JW;
    Diabetes Care; 2005 Mar; 28(3):533-8. PubMed ID: 15735183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
    Lindholm A; Jacobsen LV
    Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Explorative study of pharmacokinetics and pharmacodynamics after change in basal insulin infusion rate.
    Ihlo CA; Lauritzen T; Sturis J; Skyggebjerg O; Christiansen JS; Laursen T
    J Diabetes Sci Technol; 2011 Jan; 5(1):120-8. PubMed ID: 21303634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
    Heise T; Eckers U; Kanc K; Nielsen JN; Nosek L
    Diabetes Technol Ther; 2008 Dec; 10(6):479-85. PubMed ID: 19049377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.
    Bode BW; Strange P
    Diabetes Care; 2001 Jan; 24(1):69-72. PubMed ID: 11194244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice.
    Evans M; Ceriello A; Danne T; De Block C; DeVries JH; Lind M; Mathieu C; Nørgaard K; Renard E; Wilmot EG
    Diabetes Obes Metab; 2019 Sep; 21(9):2039-2047. PubMed ID: 31144428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
    Bode B; Weinstein R; Bell D; McGill J; Nadeau D; Raskin P; Davidson J; Henry R; Huang WC; Reinhardt RR
    Diabetes Care; 2002 Mar; 25(3):439-44. PubMed ID: 11874927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
    Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
    Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
    Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
    Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): A Single-Center, Open-Label, Randomized, Crossover Trial.
    Lane WS; Weinrib SL; Lawrence MJ; Lane BC; Jarrett RT
    Endocr Pract; 2022 Feb; 28(2):165-172. PubMed ID: 34763071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus.
    Petersen SB; Kildegaard J; Nielsen FS; Søndergaard E; Parkner T; Laursen T; Lauritzen T; Skyggebjerg O; Christiansen JS
    Diabetes Obes Metab; 2010 Apr; 12(4):334-40. PubMed ID: 20380654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming.
    Cengiz E; Weinzimer SA; Sherr JL; Tichy EM; Carria L; Cappiello D; Steffen A; Tamborlane WV
    Diabetes Technol Ther; 2014 Jan; 16(1):20-5. PubMed ID: 24367934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy.
    Swan KL; Dziura JD; Steil GM; Voskanyan GR; Sikes KA; Steffen AT; Martin ML; Tamborlane WV; Weinzimer SA
    Diabetes Care; 2009 Feb; 32(2):240-4. PubMed ID: 19017777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.